中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(3): 489-495

Efficacy of ursodeoxycholic acid in the prevention and treatment of COVID-19 in patients with chronic hepatitis B

DOI: 10.12449/JCH240309
  • 1.

    Center of Integrated Traditional Chinese and Western Medicine，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

  • 2.

    Center of Integrated Traditional Chinese and Western Medicine，Peking University Ditan Teaching Hospital，Beijing 100015，China

Research funding:

Natural Science Foundation of Beijing (7212053)

More Information
  • Corresponding author: LI Xin， leaxin@ccmu.edu.cn （ORCID： 0000-0002-2460-8753）
  • Received Date: 2023-06-06
  • Accepted Date: 2023-07-21
  • Published Date: 2024-03-20
    Abstract
  •   Objective  To investigate the potential effect of ursodeoxycholic acid （UDCA） in the prevention and treatment of COVID-19 in patients with chronic hepatitis B.  Methods  Clinical data were collected from 324 patients with chronic hepatitis B who were treated in Beijing Ditan Hospital， Capital Medical University， from January to December 2022， and according to whether UDCA was administered， they were divided into UDCA group and control group. The propensity score matching （PSM） method was used to balance the confounding factors such as age， sex， and chronic complications， and the two groups were compared in terms of SARS-CoV-2 infection rate， symptoms， and recovery time after COVID-19. The two groups were also compared in terms of related laboratory markers （white blood cell count ［WBC］， hemoglobin ［Hb］， platelet count ［PLT］， alanine aminotransferase ［ALT］， aspartate aminotransferase ［AST］， albumin ［Alb］， alkaline phosphatase ［ALP］， total bilirubin ［TBil］， triglyceride ［TG］， and total cholesterol ［TC］）， vaccination， and the incidence rate of liver disease symptoms after COVID-19. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U test was used for comparison of data with skewed distribution between the two groups； the chi-square test and the continuously corrected chi-square test were used for comparison of categorical data between two groups. The binary Logistic regression model was used for univariate and multivariate analyses to investigate the influencing factors for COVID-19 after matching.  Results  There were 87 patients in the UDCA group and 237 patients in the control group， and after PSM， there were 78 patients in the UDCA group and 137 patients in the control group， with good balance between the two groups. There was a significant difference in SARS-CoV-2 infection rate between the UDCA group and the control group ［82.1% （64/78） vs 95.6% （131/137）， χ2=10.847， P=0.001］. After COVID-19， compared with the control group， the UDCA group had a significantly lower proportion of the patients with chill （10.9% vs 38.9%， χ2=16.124， P<0.001） and cough （56.3% vs 74.8%， χ2=6.889， P=0.009）. There was a significant difference between the UDCA group and the control group in the proportion of the patients with a recovery time of ≤7 days after COVID-19 （79.7% vs 61.1%， χ2=6.760， P=0.009）. Both univariate and multivariate logistic regression analyses showed that UDCA was an independent influencing factor for COVID-19 （odds ratio=0.21 and 0.17， both P<0.05）.  Conclusion  UDCA is an protective factor against COVID-19 in patients with chronic hepatitis B and can alleviate related symptoms to some extent and shorten the recovery time， and therefore， it has an important value in the prevention and treatment of COVID-19.

     

    • FullText(HTML)
  • loading
    • References(30)
  • [1]
    LI Q, GUAN X, WU P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia[J]. N Engl J Med, 2020, 382( 13): 1199- 1207. DOI: 10.1056/NEJMoa2001316.
    [2]
    GARG S, KIM L, WHITAKER M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019- COVID-NET, 14 States, March 1-30, 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69( 15): 458- 464. DOI: 10.15585/mmwr.mm6915e3.
    [3]
    VERITY R, OKELL LC, DORIGATTI I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis[J]. Lancet Infect Dis, 2020, 20( 6): 669- 677. DOI: 10.1016/S1473-3099(20)30243-7.
    [4]
    YANG X, YU Y, XU J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8( 5): 475- 481. DOI: 10.1016/S2213-2600(20)30079-5.
    [5]
    WHO. Weekly epidemiological update on COVID-19- 22 March 2023[EB/OL].[ 2023-03-22]. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-22-march-2023. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-22-march-2023
    [6]
    LI G, de CLERCQ E. Therapeutic options for the 2019 novel coronavirus(2019-nCoV)[J]. Nat Rev Drug Discov, 2020, 19( 3): 149- 150. DOI: 10.1038/d41573-020-00016-0.
    [7]
    CHEN YC, HUANG WX. Expert consensus on the application of azvudine in the treatment of SARS-CoV-2 infection[J]. China Pharm, 2023, 32( 3): 1- 6. DOI: 10.3969/j.issn.1006-4931.2023.03.001.

    陈勇川, 黄文祥. 阿兹夫定片在新型冠状病毒感染救治中应用的专家共识[J]. 中国药业, 2023, 32( 3): 1- 6. DOI: 10.3969/j.issn.1006-4931.2023.03.001.
    [8]
    BREVINI T, MAES M, WEBB GJ, et al. FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2[J]. Nature, 2023, 615( 7950): 134- 142. DOI: 10.1038/s41586-022-05594-0.
    [9]
    YE H, DENG SW. Clinical evaluation of taurine ursodeoxycholic acid in the treatment of chronic hepatitis B with overlapping hepatitis E infection[J]. Chin Foreign Med Res, 2019, 17( 8): 47- 48. DOI: 10.14033/j.cnki.cfmr.2019.08.022.

    叶昊, 邓盛微. 牛磺酸熊去氧胆酸治疗慢性乙型肝炎重叠戊型肝炎感染的临床价值评价[J]. 中外医学研究, 2019, 17( 8): 47- 48. DOI: 10.14033/j.cnki.cfmr.2019.08.022.
    [10]
    van den BOSSCHE L, HINDRYCKX P, DEVISSCHER L, et al. Ursodeoxycholic acid and its taurine- or glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice[J]. Appl Environ Microbiol, 2017, 83( 7): e02766-16. DOI: 10.1128/AEM.02766-16.
    [11]
    SUN XL, HU X, ZHANG YT. Clinical application of ursodeoxycholic acid[J]. Chin J Pharmacov, 2022, 19( 10): 1149- 1153. DOI: 10.19803/j.1672-8629.20210604.

    孙雪林, 胡欣, 张亚同. 熊去氧胆酸的临床应用进展[J]. 中国药物警戒, 2022, 19( 10): 1149- 1153. DOI: 10.19803/j.1672-8629.20210604.
    [12]
    LI YG, ZHU ZH. Efficacy of tenofovir combined with ursodeoxycholic acid in outpatient treatment of chronic hepatitis B[J]. Health Med Res Prac, 2022, 19( 4): 22- 26, 37. DOI: 10.11986/j.issn.1673-873X.2022.04.006.

    李玉刚, 朱增红. 替诺福韦联合熊去氧胆酸对慢性乙型肝炎的疗效观察[J]. 保健医学研究与实践, 2022, 19( 4): 22- 26, 37. DOI: 10.11986/j.issn.1673-873X.2022.04.006.
    [13]
    REIFFEL JA. Propensity score matching: The‘devil is in the details’ where more may be hidden than you know[J]. Am J Med, 2020, 133( 2): 178- 181. DOI: 10.1016/j.amjmed.2019.08.055.
    [14]
    Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Infect Dis Info, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.

    中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
    [15]
    National Health Commission of the People’s Republic of China. Diagnosis and Treatment of COVID-19(Trial Version 10)[J]. Chin J Rational Drug Use, 2023, 20( 1): 1- 11. DOI: 10.3969/j.issn.2096-3327.2023.01.001.

    中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版)[J]. 中国合理用药探索, 2023, 20( 1): 1- 11. DOI: 10.3969/j.issn.2096-3327.2023.01.001.
    [16]
    ZAMPINO R, MELE F, FLORIO LL, et al. Liver injury in remdesivir-treated COVID-19 patients[J]. Hepatol Int, 2020, 14( 5): 881- 883. DOI: 10.1007/s12072-020-10077-3.
    [17]
    WANG Q, GUO Y, IKETANI S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5[J]. Nature, 2022, 608( 7923): 603- 608. DOI: 10.1038/s41586-022-05053-w.
    [18]
    QIN SL, WANG YT, CAI XJ, et al. Research progress on anti- coronavirus drugs[J]. Chin J Comp Med, 2022, 32( 6): 105- 110. DOI: 10.3969/j.issn.1671-7856.2022.06.016.

    秦聖乐, 王玉涛, 蔡雪君, 等. 抗冠状病毒药物研究进展[J]. 中国比较医学杂志, 2022, 32( 6): 105- 110. DOI: 10.3969/j.issn.1671-7856.2022.06.016.
    [19]
    GAZIANO L, GIAMBARTOLOMEI C, PEREIRA AC, et al. Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19[J]. Nat Med, 2021, 27( 4): 668- 676. DOI: 10.1038/s41591-021-01310-z.
    [20]
    FUCHS CD, TRAUNER M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology[J]. Nat Rev Gastroenterol Hepatol, 2022, 19( 7): 432- 450. DOI: 10.1038/s41575-021-00566-7.
    [21]
    WANG CH, YAO XW, WANG R, et al. The latest research progress of novel coronavirus“Omicron sub-variant BA.5”[J]. J Hanan Med Coll, 2022, 28( 20): 1521- 1525. DOI: 10.13210/j.cnki.jhmu.20220909.002.

    王彩红, 姚晓文, 王蓉, 等. 新冠病毒“奥密克戎亚变体BA.5”的最新研究进展[J]. 海南医学院学报, 2022, 28( 20): 1521- 1525. DOI: 10.13210/j.cnki.jhmu.20220909.002.
    [22]
    LEVIN EG, LUSTIG Y, COHEN C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months[J]. N Engl J Med, 2021, 385( 24): e84. DOI: 10.1056/NEJMoa2114583.
    [23]
    BERGWERK M, GONEN T, LUSTIG Y, et al. Covid-19 breakthrough infections in vaccinated health care workers[J]. N Engl J Med, 2021, 385( 16): 1474- 1484. DOI: 10.1056/NEJMoa2109072.
    [24]
    WANG SJ. Treatment of chronic hepatitis B focuses on improving disease resistance[J]. Guangming J Chin Med, 2012, 27( 8): 1497- 1499. DOI: 10.3969/j.issn.1003-8914.2012.08.003.

    王素君. 慢性乙型肝炎治疗重在提高抗病力[J]. 光明中医, 2012, 27( 8): 1497- 1499. DOI: 10.3969/j.issn.1003-8914.2012.08.003.
    [25]
    CHEN C. Zhang Xuqing: Can patients with liver disease be vaccinated with COVID-19 vaccine?[J]. Liver Doctor, 2021, 3: 8- 9.

    陈词. 张绪清: 肝病患者能否接种新冠肺炎疫苗?[J]. 肝博士, 2021, 3: 8- 9.
    [26]
    National Health Commission of the People’s Republic of China. Notice on further optimizing and implementing Measures for the prevention and control of COVID-19[EB/OL].[ 2022-12-07]. http://www.nhc.gov.cn/xcs/gzzcwj/202212/8278e7a7aee34e5bb378f0e0fc94e0f0.shtml. http://www.nhc.gov.cn/xcs/gzzcwj/202212/8278e7a7aee34e5bb378f0e0fc94e0f0.shtml

    中华人民共和国国家卫生健康委员会. 关于进一步优化落实新冠肺炎疫情防控措施的通知[EB/OL].[ 2022-12-07]. http://www.nhc.gov.cn/xcs/gzzcwj/202212/8278e7a7aee34e5bb378f0e0fc94e0f0.shtml. http://www.nhc.gov.cn/xcs/gzzcwj/202212/8278e7a7aee34e5bb378f0e0fc94e0f0.shtml
    [27]
    BEUERS U, TRAUNER M, JANSEN P, et al. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond[J]. J Hepatol, 2015, 62( 1 Suppl): S25- S37. DOI: 10.1016/j.jhep.2015.02.023.
    [28]
    LIU Y, FENG Y, REN J, et al. The influencing factors of abnormal liver function in patients with COVID-19 and its dynamic changes in different drug treatments[J]. J Capit Med Univ, 2022, 43( 3): 433- 439. DOI: 10.3969/j.issn.1006-7795.2022.03.017.

    刘遥, 冯颖, 任婕, 等. 新型冠状病毒肺炎患者肝功能异常的影响因素及其在不同药物治疗中的动态变化[J]. 首都医科大学学报, 2022, 43( 3): 433- 439. DOI: 10.3969/j.issn.1006-7795.2022.03.017.
    [29]
    DAVIES MA, MORDEN E, ROSSEAU P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa[J]. Int J Infect Dis, 2023, 127: 63- 68. DOI: 10.1016/j.ijid.2022.11.024.
    [30]
    LEI SY, PENG H, LUO XH. Pathogenic mechanism of liver injury caused by coronavirus disease 2019 and protective strategies for patients with viral hepatitis cirrhosis[J]. J Clin Hepatol, 2020, 36( 7): 1619- 1622. DOI: 10.3969/j.issn.1001-5256.2020.07.037.

    雷偲艺, 彭虹, 罗新华. 新型冠状病毒肺炎引起肝损伤的致病机制及病毒性肝炎肝硬化患者的防护策略[J]. 临床肝胆病杂志, 2020, 36( 7): 1619- 1622. DOI: 10.3969/j.issn.1001-5256.2020.07.037.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (433) PDF downloads(70) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return